Results 181 to 190 of about 3,116,614 (307)

Novel therapies for children with acute myeloid leukaemia [PDF]

, 2013
Significant improvements in survival for children with acute myeloid leukaemia (AML) have been made over the past three decades, with overall survival rates now approximately 60-70%. However, these gains can be largely attributed to more intensive use of
Kearns, P. R., Knapper, S., Moore, A. S., Pearson, A. D. J., Zwaan, C. M.   +4 more
core   +1 more source

High levels of serum cholesterol increase the risk of developing vessel co‐opting tumors in colorectal cancer liver metastases

The FEBS Journal, EarlyView.
High serum cholesterol is linked to colorectal cancer liver metastases (CRCLM) subtypes with poor survival (replacement pattern). Levels of cholesterol under 4 mmol·L−1 correlated with better survival and a desmoplastic pattern subtype. Furthermore, in vivo PCSK9 inhibitor evolocumab, which lowers cholesterol, reduced liver metastases.
Amatzia Gantz, Audrey Kapelanski‐Lamoureux, Miran Rada, Lucyna Krzywon, Migmar Tsamchoe, Anastasia Tsatoumas, Stephanie K. Petrillo, Nabil G. Seidah, Anthoula Lazaris, Peter Metrakos   +9 more
wiley   +1 more source

Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study

Hepatology Research, EarlyView.
In this real‐world post‐ICI setting, cabozantinib demonstrated meaningful clinical activity even at reduced doses, with disease control achieved in nearly half of patients. Importantly, preserved liver function (Child–Pugh class A) was the only determinant of both disease control and overall survival.
Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi, Mizuki Ariga, Sayaka Morisaki, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara, Yoshiki Hirooka   +13 more
wiley   +1 more source

Angiopoietin‐like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma [PDF]

, 2016
Hsin‐An Chen, Tsang‐Chih Kuo, Chi‐Feng Tseng, Jui‐Ti Ma, Shuting Yang, Chia‐Jui Yen, Ching‐Yao Yang, Shian‐Ying Sung, Jen‐Liang Su   +8 more
openalex   +1 more source

MiR-30e-3p Influences Tumor Phenotype through MDM2 / TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma [PDF]

, 2020
Laura Gramantieri, Daniela Pollutri, Martina Gagliardi, Catia Giovannini, Santina Quarta, Manuela Ferracin, Andrea Casadei‐Gardini, Elisa Callegari, Sabrina De Carolis, Sara Marinelli, Francesca Benevento, Francesco Vasuri, Matteo Ravaioli, Matteo Cescon, Fabio Piscaglia, Massimo Negrini, Luigi Bolondi, Francesca Fornari   +17 more
openalex   +1 more source

PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells [PDF]

, 2021
Jiunn-Chang Lin, Pei‐Ming Yang, Tsang‐Pai Liu   +2 more
openalex   +1 more source

NCOA5 induces sorafenib resistance in hepatocellular carcinoma by inhibiting ferroptosis

Cell Death Discovery
Abstract NCOA5 has been identified as a crucial factor in the progression of hepatocellular carcinoma (HCC). This study investigates the expression of NCOA5 in HCC, revealing its significant overexpression in tumor tissues compared to healthy liver tissues, as evidenced by analysis of the TCGA dataset and RT-qPCR in patient samples.
Shuang Gao, Lulu Fan, Huiyan Wang, Anqi Wang, Mengyao Hu, Lei Zhang, Guoping Sun   +6 more
openaire   +3 more sources

Impact of Early‐Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti‐VEGF Agents

Hepatology Research, EarlyView.
ABSTRACT Background and Aim Anti–vascular endothelial growth factor (VEGF) agents are widely used for hepatocellular carcinoma (HCC); inhibition of VEGF‐mediated liver regeneration may compromise hepatic reserve. We investigated the impact of anti‐VEGF therapy on liver function and risk factors for deterioration of albumin–bilirubin (ALBI) score during
Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki, Takuya Matsubara, Naoya Omaru, Natsuki Okai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Masatoshi Kudo   +11 more
wiley   +1 more source

Primary and Secondary Grzybowski’s Generalized Eruptive Keratoacanthoma: A New Perspective on Management, Clinical Features, and Prognosis

International Journal of Dermatology, EarlyView.
ABSTRACT Grzybowski's generalized eruptive keratoacanthoma (GEKA) is a rare variant of keratoacanthomas, characterized by hundreds to thousands of lesions, accompanied by pruritus, mucosal involvement, and comorbidities. Our aim was to analyze the clinical presentation, associated comorbidities, treatment strategies, and outcomes of GEKA.
Nicholas Florin Kormos, Carina Maria Petrenciu, Alin Stefan Vizitiu, Raluca Ghețe, Umer Nadir, Adrian Lucian Baican, Stanislav N. Tolkachjov   +6 more
wiley   +1 more source

Prospects for non-immunological molecular therapeutics in melanoma [PDF]

, 2010
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 13,000 deaths (www.europeancancerleagues.org). Currently available systemic treatment options for metastatic melanoma, including both cytotoxic and immunologic therapies,
Crown, John, Eustace, Alexander J., Mahgoub, Thamir, O'Donovan, Norma, Tryfonopoulos, Dimitrios   +4 more
core